ARS Pharmaceuticals (SPRY) Operating Leases (2020 - 2025)

ARS Pharmaceuticals has disclosed Operating Leases across 5 years of filings, most recently posting $949000.0 for Q3 2025.

• Operating Leases for Q3 2025 came in at $949000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $949000.0 (changed N/A YoY), and the FY2023 annual result was $37000.0, down 85.26% from the prior year.
• Operating Leases came in at $949000.0 for Q3 2025 at ARS Pharmaceuticals, down from $1.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $5.1 million in Q3 2021 to a low of $37000.0 in Q4 2023.
• The 4-year median for Operating Leases is $949000.0 (2025), against an average of $1.7 million.
• Across the five-year window, Operating Leases soared 128.63% in 2022 and sank 96.41% in 2023, its largest moves.
• ARS Pharmaceuticals' Operating Leases stood at $480000.0 in 2021, then sank by 47.71% to $251000.0 in 2022, then sank by 85.26% to $37000.0 in 2023, then jumped by 2464.86% to $949000.0 in 2025.
• The last three Operating Leases figures came in at $949000.0 (Q3 2025), $1.1 million (Q2 2025), and $37000.0 (Q4 2023), per Business Quant data.